Medscape1mon
A Novel Patch for Heart Rhythm Monitoring
recording an average of over 7 days of heart monitoring. Despite US FDA approval, the Zio Patch has met slow acceptance possibly due to reimbursement hurdles. Explanations for the slow acceptance ...
Morningstar3d
SmartCardia Receives FDA Clearance for Outpatient Cardiac Telemetry for Its 7-Lead ECG Patch and Cloud Platform
LAUSANNE, Switzerland, Nov. 13, 2024 /PRNewswire/ -- SmartCardia has received FDA clearance for Mobile Outpatient Cardiac Telemetry (OCT/MCT) for its 7-lead live ECG monitoring patch and cloud ...
medtechdive14d
FDA clears iRhythm’s second 510(k) in response to warning letter
However, the company said it will delay a submission for its next-generation Zio cardiac monitoring system until remediation ...
Yahoo Finance25d
iRhythm Technologies Stock Rises Post FDA Clearance for Zio AT
system for outpatient cardiac monitoring. It includes the Zio AT patch, which records ECG data for up to 14 days, and a wireless gateway that transmits data to iRhythm's Zio ECG Utilization ...
iRhythm Technologies Receives FDA 510(k) Clearance for Design Modifications to Its Zio® AT Device
Detailed price information for Irhythm Technologies Inc (IRTC-Q) from The Globe and Mail including charting and trades.
Mena FN3d
Smartcardia Receives FDA Clearance For Outpatient Cardiac Telemetry For Its 7-Lead ECG Patch And Cloud Platform
The company was honoured with the 2022 Global New Product Innovation Award in cardiac monitoring from Frost & Sullivan. SmartCardia is a leading provider of an integrated cloud platform and patch ...